- Home
- SLGL vs ABVC Comparison
SLGL vs ABVC Comparison
Compare SLGL & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- ABVC
- Stock Information
- Founded
- SLGL 1997
- ABVC 2015
- Country
- SLGL Israel
- ABVC United States
- Employees
- SLGL N/A
- ABVC N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- ABVC Health Care
- Exchange
- SLGL Nasdaq
- ABVC Nasdaq
- Market Cap
- SLGL 49.4M
- ABVC 52.1M
- IPO Year
- SLGL 2018
- ABVC N/A
- Fundamental
- Price
- SLGL $23.48
- ABVC $2.98
- Analyst Decision
- SLGL Buy
- ABVC
- Analyst Count
- SLGL 1
- ABVC 0
- Target Price
- SLGL $40.00
- ABVC N/A
- AVG Volume (30 Days)
- SLGL 30.1K
- ABVC 182.9K
- Earning Date
- SLGL 08-15-2025
- ABVC 08-13-2025
- Dividend Yield
- SLGL N/A
- ABVC N/A
- EPS Growth
- SLGL N/A
- ABVC N/A
- EPS
- SLGL N/A
- ABVC N/A
- Revenue
- SLGL $23,931,000.00
- ABVC $391,242.00
- Revenue This Year
- SLGL N/A
- ABVC $735.18
- Revenue Next Year
- SLGL $31.17
- ABVC N/A
- P/E Ratio
- SLGL N/A
- ABVC N/A
- Revenue Growth
- SLGL 264.86
- ABVC 186.84
- 52 Week Low
- SLGL $4.01
- ABVC $0.40
- 52 Week High
- SLGL $26.89
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- SLGL 72.14
- ABVC 49.89
- Support Level
- SLGL $20.06
- ABVC $2.85
- Resistance Level
- SLGL $26.89
- ABVC $3.36
- Average True Range (ATR)
- SLGL 2.57
- ABVC 0.24
- MACD
- SLGL 0.63
- ABVC -0.01
- Stochastic Oscillator
- SLGL 75.10
- ABVC 49.37
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.